Table I.
Demographics and clinical characteristics of the study population.
| Variable | No. (n=72) |
|---|---|
| Age (years) | 47 (36–53) |
| Sex, female [n (%)] | 14 (19.4) |
| MSM [n (%)] | 40 (56) |
| Time since HIV diagnosis (months) | 122 (59–200) |
| Current CD4+ T-cell count (cells/µl) | 605 (409–789) |
| HIV viral load <50 copies/ml [n (%)] | 59 (82) |
| Time on cART (months) | 72 (31–191) |
| Current use of PI [n (%)] | 27 (37.5) |
| Current use of TDF [n (%)] | 57 (79.2) |
| Current use of raltegravir [n (%)] | 10 (13.9) |
| BMI (kg/m2) | 24 (22–26.6) |
| Current smoking [n (%)] | 26 (36.1) |
| Hepatitis C coinfection [n (%)] | 6 (8.3) |
| Diabetes mellitus [n (%)] | 5 (6.9) |
| Hypertension [n (%)] | 13 (18.1) |
| Dyslipidemia [n (%)] | 22 (30.6) |
| Framingham risk score (%) | 4.5 (1–11.2) |
| eGFR (ml/min/1.73 m2), based on CKD-EPI formula | 96.9±18.5 |
| Proteinuria [n (%)] | 23 (32) |
| Microalbuminuria [n (%)] | 18 (25) |
| hs-CRP (ng/ml) | 0.18 (0.07–0.47) |
| ANGPTL2 (ng/ml) | 2.09 (1.45–3.03) |
| sCD14 (ng/ml) | 1,969 (1,747–2,292) |
Data are mean ± standard deviation or median (interquartile range), unless otherwise specified. ANGPTL2, angiopoietin-like protein 2; BMI, body mass index; cART, combination antiretroviral therapy; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; HIV, human immunodeficiency virus; hs-CRP, highly sensitive-C reactive protein; MSM, men having sex with men; PI, protease inhibitor; sCD14, soluble CD14; TDF, tenofovir.